Nuvance Health
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 2019-01-01
- Employees
- -
- Market Cap
- -
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Nuvance Health
- Target Recruit Count
- 200
- Registration Number
- NCT04406831
- Locations
- ๐บ๐ธ
Nuvance Health, Norwalk, Connecticut, United States
A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Nuvance Health
- Target Recruit Count
- 800
- Registration Number
- NCT03937453
- Locations
- ๐บ๐ธ
Nuvance Health, Norwalk, Connecticut, United States
A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Nuvance Health
- Target Recruit Count
- 200
- Registration Number
- NCT03250078
- Locations
- ๐บ๐ธ
Nuvance Health, Norwalk, Connecticut, United States
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Nuvance Health
- Registration Number
- NCT00046826
- Locations
- ๐บ๐ธ
Whittingham Cancer Center at Norwalk Hospital, Norwalk, Connecticut, United States
๐บ๐ธCarl and Dorothy Bennett Cancer Center at Stamford Hospital, Stamford, Connecticut, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath